Althaf Umar K P, Anagha R Anil, Sreeja C Nair, Kanthlal S K
{"title":"Nanoparticle-based approaches for vascular inflammation in managing hypertension: advancing molecular mechanisms and treatment strategies.","authors":"Althaf Umar K P, Anagha R Anil, Sreeja C Nair, Kanthlal S K","doi":"10.1007/s13346-025-01881-1","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension is a global health challenge associated with significant morbidity and mortality resulting from vascular inflammation and endothelial dysfunction. Chronic hypertension is characterised by endothelial dysfunction, oxidative stress, immune cell recruitment, and cytokine release, all of which exacerbate vascular inflammation. Despite the availability of various antihypertensive therapies, limitations such as drug resistance and suboptimal targeting hinder their efficacy and reveal their side effects. Nanoparticle-based strategies could present innovative solutions by enabling precise drug delivery, minimising off-target effects, and enhancing therapeutic outcomes. Dual-targeting approaches that focus on molecular mechanistic pathways for managing hypertension using nanoparticle-based methods allow targeted modulation of inflammatory pathways as well. This advancement aids in redefining the management of vascular inflammation as a transformative frontier in antihypertensive therapy, addressing the unmet need for targeted, efficient, and patient-tailored treatment strategies. This review outlines the inflammatory pathophysiology underlying vascular hypertension and underscores the necessity of integrating knowledge gaps while inspiring innovative approaches to combat hypertension effectively. It concludes by identifying potential obstacles and solutions to overcome in order to successfully translate such nano-derived therapies into clinical practice applications.</p>","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery and Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13346-025-01881-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension is a global health challenge associated with significant morbidity and mortality resulting from vascular inflammation and endothelial dysfunction. Chronic hypertension is characterised by endothelial dysfunction, oxidative stress, immune cell recruitment, and cytokine release, all of which exacerbate vascular inflammation. Despite the availability of various antihypertensive therapies, limitations such as drug resistance and suboptimal targeting hinder their efficacy and reveal their side effects. Nanoparticle-based strategies could present innovative solutions by enabling precise drug delivery, minimising off-target effects, and enhancing therapeutic outcomes. Dual-targeting approaches that focus on molecular mechanistic pathways for managing hypertension using nanoparticle-based methods allow targeted modulation of inflammatory pathways as well. This advancement aids in redefining the management of vascular inflammation as a transformative frontier in antihypertensive therapy, addressing the unmet need for targeted, efficient, and patient-tailored treatment strategies. This review outlines the inflammatory pathophysiology underlying vascular hypertension and underscores the necessity of integrating knowledge gaps while inspiring innovative approaches to combat hypertension effectively. It concludes by identifying potential obstacles and solutions to overcome in order to successfully translate such nano-derived therapies into clinical practice applications.
期刊介绍:
The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions.
Research focused on the following areas of translational drug delivery research will be considered for publication in the journal.
Designing and developing novel drug delivery systems, with a focus on their application to disease conditions;
Preclinical and clinical data related to drug delivery systems;
Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
Short-term and long-term biocompatibility of drug delivery systems, host response;
Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering;
Image-guided drug therapy,
Nanomedicine;
Devices for drug delivery and drug/device combination products.
In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.